Just-In-Time Adaptive Interventions for Addictive Behaviors

Phase

N/A

Condition

Substance Abuse

Treatment

Placebo

Formative Interviews (not an intervention)

No intervention

Clinical Study ID

NCT03538652

999918095

18-DA-N095

Ages 18-75
All Genders

Study Summary

Background:

Many smartphone apps intend to help people with addictions. But not enough is known about how they should work. Researchers want to study an app that gives people the advice they need, just when they need it. This is a Just-In-Time Adaptive Intervention (JITAI). To create a good JITAI, researchers need to know what approaches work best at different moments.

Objective:

To develop ways to treat addiction with a smartphone app.

Eligibility:

Adults ages 18-75 who use heroin or other opioids

Design:

Participants will be screened in another protocol.

Participants will visit a Baltimore clinic 3 days a week to give urine and breath samples.

Some participants will get their treatment at this clinic.

Participants will answer questions about their personality and stress.

Participants will randomly be assigned to the JITAI group or a comparison group.

Participants will have a training session on using the smartphone app. JITAI participants will also watch a video about the written messages they will see in the app.

Weeks 3-10: Participants will carry a smartphone. Four times a day, it will beep and ask questions. These will be about the participants' activities and mood. The JITAI group will see a short message after. The message is meant to be helpful.

For the first 16 evenings, JITAI participants will get more information on the phone.

Answers to the app's questions will be transferred automatically from the smartphone to secure computers at the NIH.

During the last week, participants can choose the kind of messages they see.

Week 11: participants will return the smartphone and answer questions.

Weeks 12-16, participants who are getting their medicine from the research clinic will be encouraged to transfer to other clinics. Otherwise, they will have their dose slowly reduced to zero.

Eligibility Criteria

Inclusion

INCLUSION CRITERIA:

Phase 1: Formative interviews.

The enrollment ceiling is 35 outpatients (to collect evaluable data from 30) who meet these criteria: (1) Age 18-75; (2) physical dependence on opioids (by self-report); (3) interest in receiving the types of treatment about which we will be conducting interviews.

Phase 2: Clinical trial with microrandomization.

The enrollment ceiling is 150 outpatients (to collect evaluable data from 85, of whom 50 will be randomized to JITAI, and 35 to EMA control). Treatment may be provided by us in the form of office-based buprenorphine treatment (OBOT) or may be provided elsewhere (Treatment Elsewhere, TE).

Participants must meet these criteria:

OBOT participants: (1) Age 18-75; (2) physical dependence on opioids (by positive urine and/or frank opioid withdrawal); (3) interest in receiving the types of treatment we are testing.

Treatment Elsewhere (TE) participants: (1) Age 18-75; (2) receiving methadone or buprenorphine treatment for opioid dependence from a qualified provider in the community; (3) interest in receiving the types of treatment we are testing.

Exclusion

EXCLUSION CRITERIA:

Phase 1: Formative interviews. (1) cognitive impairment severe enough to preclude informed consent or valid interview responses.

Phase 2: Clinical trial with microrandomization.

OBOT participants:

(1) History of any DSM-V psychotic disorder; history of bipolar disorder; currentMajor Depressive Disorder;
(2) unresolved symptoms of PTSD that, in the investigators view, would make it riskyfor the participant to undertake mindfulness exercises (e.g., observing all one'scurrent negative thoughts and emotions) in an unsupervised setting;
(3) current dependence on alcohol or sedative-hypnotic, e.g. benzodiazepine (byDSM-V criteria);
(4) cognitive impairment severe enough to preclude informed consent or validself-report;
(5) Any condition that interferes with urine collection;
(6) medical illness (e.g., cirrhosis, nephritic syndrome, thyroid disease, ischemicheart disease, epilepsy, adrenal insufficiency, etc.) or medications that, in theview of the investigators, would compromise participation in research.

Study Design

Placebo

February 19, 2020

March 13, 2020

Study Description

BACKGROUND: Our research group has made extensive use of ecological momentary assessment (EMA) to understand people's daily experiences with opioid craving, use, and lapse. We have also administered clinic-based psychotherapies such as cognitive-behavioral therapy (CBT), in which clients learn to avoid, escape, resolve, or reframe problems (such as stress) that can trigger lapses to drug use. CBT contrasts with ACT (Acceptance and Commitment Therapy), a mindfulness-based approach in which difficult thoughts and feelings are viewed as necessary and potentially valuable components of a full life, to be experienced observantly rather than resolved or reframed. CBT and ACT can and do coexist in a single treatment plan, but we know of no systematic attempt to reconcile their differences. We have also not tried to administer either of them on a mobile device.

OBJECTIVE: To test a just-in-time adaptive intervention (JITAI)-a treatment given when and where it is needed. Our JITAI will be delivered via smartphone app and will combine elements of two widely used treatments for addiction: CBT and ACT. Our goal is not to bring another branded app onto the market, but rather to clarify when and for whom the generic components of such apps are effective or not. This will include determining when CBT is more helpful than ACT and vice versa.

PARTICIPANT POPULATION: Outpatient adults who are physically dependent on opioids - up to 185 enrolled (35 for a formative-interview phase, 150 for a trial) for a target of 115 evaluable (30 interviewees, 85 trial participants). Target enrollment will include 40% women and 60% minorities (mostly African-American). In the trial, some participants will receive buprenorphine in our clinic, and others will be receiving buprenorphine or methadone elsewhere; this is a procedural matter, not a component of the experimental design.

EXPERIMENTAL DESIGN: After a formative-interview phase, the study will be run as a microrandomized trial that will also include a conventionally randomized between-groups clinical-trial component. In microrandomization, interventions are randomized at the momentary level within person; the effect is measured proximally (e.g., 20 minutes later). This is a powerful way to assess the effects of different interventions administered in the field and to examine strategy-situation fit, i.e., whether interventions are differentially effective under specific momentary circumstances. We are powering our study mostly to detect

(1) any effect of CBT or ACT versus control moments with no intervention given, and
(2) preferential advantages of CBT over ACT, and vice versa, as a function of the participant's ability to control (change, escape) a given situation.

The between-groups aspect of the design (JITAI group versus EMA-only control group) is needed to demonstrate an effect of our JITAI on traditional, distal measures of outcome, such as reductions in opioid use.

METHODS: In the formative-interview phase, we will conduct interviews with people in treatment for OUD who express interest in using a mobile treatment app. We will ask them about day-to-day challenges they currently face in maintaining progress toward their treatment goals, and ask them what might be helpful. Then we will show them item lists, onscreen mockups, and/or functional demos, and we will ask interviewees to comment on the app's likely usefulness, its likely pitfalls, and how we could improve it.

In the clinical trial, participants will be randomized to one of two groups (JITAI vs. EMA-only control).

During weeks 1-2, all participants will have baseline assessments of coping styles and personality, and all JITAI participants will be shown a video introducing basic concepts of CBT and ACT.
For weeks 3-10 (8 weeks), participants will carry smartphones for EMA with or without JITAI.
During week 11, participants will be readministered some of the assessments from baseline.

Participants receiving buprenorphine from us will then be offered a dose taper or encouraged to transfer to continued treatment elsewhere. All participants will come to our clinic thrice weekly for urine testing throughout participation.

PRIMARY OUTCOME MEASURES:

Proximal effects of CBT and ACT messages in the JITAI group: decreases over 20-minute intervals in craving and negative mood, with increases in self-efficacy
strategy-situation fit in the JITAI group
group differences in distal effects of treatment (week 11 versus week 2) in terms of self-efficacy and coping flexibility

SECONDARY OUTCOME MEASURES:

Trait predictors of differential responses to CBT and ACT, in the JITAI group
group differences in frequency of opioid-positive urine over time
time courses of responsiveness to ACT vs. CBT, in the JITAI group
whether the intervention types that benefit participants most when pushed by the app are the same ones participants choose when subsequently given the opportunity to pull interventions.

Connect with a study center

National Institute on Drug Abuse
Baltimore, Maryland 21224
United States
Site Not Available
National Institute on Drug Abuse
Baltimore 4347778, Maryland 4361885 21224
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.